Vytrus Biotech obtains approval for a new patent from the United States Patent and Trademark Office (USPTO). This new patent granted is suitable for skin rejuvenation and wound healing applications under the title "Cell-free plant cell culture suspension supernatant with re-youth activity and/or wound healing activity over skin cells".
The patent covers Centella Reversa™ and Clarivine™ for their applications in skin wound healing. Both actives are rich in plant peptides and natural exosomes of plant origin, highly valued in the current global dermocosmetic market.
After Europe, the United States is the company's main market, and Vytrus expects that the granting of this patent will help strengthen the expansion and consolidation of sales in this country.
Vytrus has achieved an overall growth of +76% in sales in the first three months of 2025 compared to the same period of 2024. The growth was widespread with high rates in all geographical areas where the company operates, and sales in the United States, during these first three months of the year, have grown by 27% compared to the same period of 2024.
Vytrus' sales in this first quarter reached 5.9 million euros for the first time in its history. This growth, as the company points out, has been promoted by Vytrus' assets that incorporate Exosomic Peptides technology and, led by anti-aging, hair and brightening products.
The Catalan company is already in more than 40 countries and has allowed Vytrus to increase its EBITDA by 102% compared to the same period of 2024, reaching 1.02 million euros.